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Abstract  
Autologous human keratinocytes (HK) forming sheet grafts are approved as skin substitutes. 
Genetic engineering of HK represents a promising technique to improve engraftment and 
survival of transplants. Although efficacious in keratinocyte-directed gene transfer, retro-
/lentiviral vectors may raise safety concerns when applied in regenerative medicine. We 
therefore optimized adeno-associated viral (AAV) vectors of the serotype 2, characterized by 
an excellent safety profile, but lacking natural tropism for HK, through capsid-engineering. 
Peptides, selected by AAV peptide display, engaged novel receptors that increased cell entry 
efficiency by up to 2500-fold. The novel targeting vectors transduced HK with high efficiency 
and a remarkable specificity even in mixed cultures of HK and feeder cells. Moreover, 
differentiated keratinocytes in organotypic airlifted three-dimensional cultures were 
transduced following topical vector application. By exploiting comparative gene analysis we 
further succeeded in identifying αvβ8 integrin as a target receptor thus solving a major 
challenge of directed evolution approaches and describing a promising candidate receptor for 
cutaneous gene therapy.  
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Introduction 
The skin is a highly specialized barrier that protects the organism from environmental 
challenges while preventing loss of water and small nutrients.1-2 The skin´s most outer layer, 
the epidermis, is a stratified, multi-layered epithelium consisting of the stratum basale, the 
stratum spinosum, the stratum granulosum and the stratum corneum.1-2 To maintain proper 
protection against dehydration and the environment, the barrier is not static but requires 
continuous renewal. This is achieved by a tightly controlled balance between lifelong self-
renewal of cells in the stratum basale and a strictly regulated spatiotemporal terminal 
differentiation program, which ultimately leads to the formation of the stratum corneum, 
representing a water impermeable layer of avital cornified cells.3  
Insults to the barrier including skin wounding initiate a well-coordinated process to restore 
skin barrier function that - depending on the insult - includes cell proliferation, migration, 
extracellular matrix deposition, angiogenesis and skin remodeling.4 This process fails in 
conditions of large cutaneous burns and chronic wounds. Limiting factors are the size of 
damage, an altered, inflammatory environment and/or lack of proper angiogenesis. 
Regenerative medicine has shown therapeutic promise in these settings. Specifically, 
autologous keratinocytes are grown on either artificial or natural supporting scaffolds and skin 
sheets are subsequently transplanted. Engraftment as well as wound closure can be 
significantly improved if the transplant secretes anti-inflammatory cytokines and/or growth 
factors including angiogenic mediators.5 These factors are only transiently required arguing 
for the use of non-integrating vectors for gene delivery.  
Adeno-associated virus (AAV)-based vectors - classified as non-integrating vectors - have 
emerged as one of the most promising delivery system for clinical use.6 They are of low 
immunogenicity, can be produced at very high titers and deliver DNA vector genomes, which 
form episomes serving as templates for transcription.7 The prototype AAV vector is based on 
the serotype 2 (AAV2). It can be pseudotyped with capsids of other natural occurring 
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serotypes or with engineered capsids.7 
AAV vectors have been successfully applied in over 80 clinical trials with an excellent safety 
profile.7 Clinical benefit was reported for the treatment of a range of inherited diseases such 
as hemophilia B, Leber’s congenital amaurosis or lipoprotein lipase deficiency.6 The use of 
this vector system for the treatment of inherited skin diseases or in impaired wound healing, 
however, has been hindered by the refractoriness of primary human keratinocytes towards 
AAV-mediated transduction. 8-12  
Poor transduction activity can be addressed by directing vectors towards a novel receptor that 
is expressed on the target cell, mediates vector internalization and induces a cellular program 
leading to nuclear delivery of vector genomes and transgene expression.7 To this end, vectors 
can be equipped with ligands that are either non-covalently linked or genetically incorporated 
into viral capsid or envelope proteins, a technology termed cell entry targeting or 
transductional targeting.  
Also the capsid of AAV2 tolerates genetic incorporation of peptide ligands.7 It is a 60mer 
composed of three different viral proteins (VP1 (90 kDa), VP2 (72 kDa) and VP3 (60 kDa)), 
which share most of their amino acid sequence.13 This common region (“common VP3 
region”) is frequently exploited for insertion of peptide ligands as it forms the capsid 
exterior.14 Of particular interest is amino acid position 587 located at the tip of a peak at the 
capsid’s three-fold symmetry axis.15 Its exposed position facilitates receptor binding of 
inserted peptides. Furthermore, insertions at this site disrupt the primary receptor-binding 
motif, a prerequisite for approaches aiming to re-direct the viral tropism.16-18  
Rational design-based approaches to modify the viral tropism are challenged by the limited 
knowledge on ligands capable of directing target cell transduction. We and others have 
therefore developed a high-throughput screening technique, the AAV peptide display, to 
select in a directed evolution approach and within the physiological context of the viral capsid 
for appropriate ligands.19-21  
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Here, we have exploited this technology to develop AAV targeting vectors with a striking 
tropism for primary human keratinocytes (HK). In contrast to natural occurring AAVs, these 
novel vectors efficiently transduce HK in monocultures, show a remarkable specificity for 
HK in feeder layer co-cultures and can be applied topically on airlifted three-dimensional 
(3D) organotypic skin cultures for transduction of differentiated keratinocytes. The latter 
feature is not only important in basic research, but represents a central prerequisite for future 
clinical applications. Finally, we established comparative gene analysis as a tool to identify 
receptors targeted by vectors selected in high-throughput screens. We thereby solved a major 
problem impeding the application of tropism-modified vectors and identified a novel 
candidate receptor for modifying keratinocytes in regenerative medicine and gene therapy. 
 
Results 
Primary human keratinocytes lack primary receptor for AAV2 
Previous studies have demonstrated that HK are poor targets for AAV2 vectors.8-12 In line, 
transduction of HK, isolated from foreskins of different healthy donors, did not exceed 5% 
(Fig. 1A). To unravel the cause for this refractoriness, keratinocytes were analyzed for the 
presence of receptors required for cell transduction by flow cytometry revealing that HK do 
express AAV2s’ internalization receptors αvβ5 and α5β1 integrin22-23, but lack heparan 
sulfate proteoglycan (HSPG), which serves as attachment receptor (Fig. 1B).24  
 
High-throughput selection of AAV capsid variants on primary human keratinocytes 
To re-direct the tropism of AAV vectors towards HK, we performed an AAV peptide display 
selection (Fig. S1) with a library that had been depleted for mutants displaying HSPG-binding 
peptides. Aiming to select for AAV variants that transduce HK with high efficiency and in a 
donor-independent manner, we used a different donor for each selection round and constantly 
increased the selection pressure by decreasing the number of particles from initially 1000 
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vector genome containing particles (vg) per cell to 1 vg/cell.  
After the 5th selection round, viral genomes were isolated and sequenced (Table 1). In total, 
nine different motifs were selected. With the exception of RSDLASL (Kera4) and PRGELAP 
(Kera5), all isolates encoded peptides with a RGD tripartite motif, a hallmark of integrin-
binding ligands. Furthermore, in three of the nine motifs, the structure determining amino acid 
residue proline was located in position one and seven, and in three of the nine sequences the 
RGD motif was followed by leucine-alanine (LA) or leucine-arginine (LR).  
Three motifs with an overall neutral charge were picked for further analyses. Specifically, we 
choose Kera1 (RGDTATL) and Kera3 (RGDQQSL), because of the high frequency of their 
occurrence, and Kera2 (PRGDLAP) because it contains the LA motif, the potential integrin-
binding domain and flanking proline residues, which likely stabilizes presentation of the 
inserted peptide. The three capsid variants and AAV2 were packaged as vectors with a self-
complementary vector genome encoding the enhanced green fluorescent protein (GFP) 
controlled by the cytomegalovirus (CMV) pro oter. The capsid-to-genomic particle ratio for 
the AAV targeting vectors (AAV-Kera1, AAV-Kera2 and AAV-Kera3) and for AAV2 was 
comparable (Table S1), indicating that none of the peptide insertions interfered with vector 
genome packaging.16 
 
AAV targeting vectors transduce primary human keratinocytes with high efficiency in a 
peptide-dependent manner 
To evaluate whether the targeting vectors indeed showed tropism for HK, we determined 
entry as well as transduction efficiency (Fig. 2). For all three targeting vectors a significantly 
increased number of intracellular vector genomes compared with AAV2 was measured. The 
most efficient vector, AAV-Kera2, demonstrated a 2500-fold increase, followed by AAV-
Kera3 (1700-fold) and AAV-Kera1 (1600-fold). Accordingly, also the transduction efficiency 
of the novel vectors was significantly higher compared with AAV2 (Fig. 2B). Incubating HK 
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for example with 5x10e3 vg/cell resulted in transduction efficiencies of 54.1% +/- 11.6% 
(AAV-Kera1), 46.7 %+/- 16.8% (AAV-Kera2) and 47.0%+/- 10.8% (AAV-Kera3), while 
AAV2 failed to transduce HK (1.2% +/- 0.5%) (Fig. S2). 
Next, we performed competition assays with RGD- and RGE-containing peptides to prove 
that the RGD-containing peptide insertions were responsible for the improved transduction 
(Fig. 2C). As control, we included AAV2 with an almost 7-fold higher vg/cell ratio than the 
targeting vectors. However, this was still not sufficient to achieve a transduction efficiency 
above background level (Fig. 2C). In contrast, all three targeting vectors transduced HK with 
a vg/cell ratio of 7.5x10e2 with efficiencies of 51.0% +/- 4.2% (AAV-Kera3) or higher. 
Transduction of HK by the three targeting vectors was significantly reduced in the presence of 
RGD-containing peptides, while addition of RGE-containing peptides did not compete with 
vector-mediated cell transduction (Fig. 2C). The most dramatic decrease in cell transduction 
by addition of the RGD-containing peptide was observed for AAV-Kera2.  
 
AAV targeting vectors demonstrate re-directed tropism 
Having demonstrated a tropism for HK, we were interested in studying the interaction with 
cell types representing potential off-targets in cutaneous gene therapy approaches. To this 
end, we compared transduction efficiencies of AAV2 and our targeting vectors on fibroblasts 
(using NIH3T3 fibroblasts), melanocytes (using BML melanoma cells) and liver cells (using 
HepG2 hepatoma cells). Specifically, fibroblasts were used since this cell type is not only 
frequently found in the dermis but because fibroblasts are used as feeder cells for ex vivo 
keratinocyte cultures during tissue engineering. Melanocytes were exploited as further 
example of a specialized cell type of the epidermis and liver cells were chosen since AAV2 
tend to accumulate in liver tissue, following both local as well as intravenous application.  
All cell lines were transduced in a dose-dependent manner by AAV2 highlighting the broad 
tropism of AAV vectors with wild-type capsids (Fig. 3). HepG2 cells showed the highest 
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level with up to 77.3% +/- 3.1% of transduced cells, followed by BLM cells. The lowest 
transduction efficiency was measured for NIH3T3 cells (24.3% +/- 3.6%). In contrast, 
transduction efficiencies of AAV-Kera1, AAV-Kera2 and AAV-Kera3 remained at 
background level even at a vg/cell ratio of 5x10e3. 
Since many standard HK cell cultures rely on the use of fibroblast feeder layers we aimed to 
evaluate whether our targeting vectors retain tropism for keratinocytes under the specific 
conditions of such co-cultures. We therefore incubated co-cultures of HK and NIH3T3 cells 
with AAV-Kera1, AAV-Kera2 and AAV-Kera3, respectively. As indicated in Fig. 4, all three 
targeting vectors showed a remarkable preference for keratinocytes. The most striking results 
were obtained with AAV-Kera2, which transduced 83.8% of keratinocytes, while only 7.1% 
of the fibroblasts were positive for GFP.  
 
Transduction of differentiated keratinocytes in human organotypic skin cultures 
Upon exposure to an air-liquid interface keratinocytes form a multi-layered epidermis that 
mimics an in vivo stratified epidermis including a stratum corneum.25 These 3D organotypic 
skin cultures serve as model system for functional testing in basic and applied research.25 
However, at present, keratinocytes have to be genetically manipulated prior to seeding due to 
inefficiency of in situ gene transfer thus limiting the use of such cultures. We therefore 
assessed whether our targeting vectors - when applied on the top layer of 16-day-old 
organotypic skin cultures - transduce keratinocytes following multi-layer formation, i.e. 
following differentiation. While no positive cells could be detected in PBS- or AAV2-treated 
cultures (Fig. 5A), strong GFP signals were seen in the most upper layers of AAV-Kera2- and 
AAV-Kera3-treated 3D skin cultures with AAV-Kera2 also showing strong staining in lower 
keratinocyte layers (Fig. 5B). Only weak GFP signals were detected in the AAV-Kera1-
treated culture, suggesting that AAV-Kera1 was less efficient in transducing differentiated 
keratinocytes (Fig. 5B).  
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AAV targeting vectors transduce primary murine keratinocytes 
Besides HK, primary murine keratinocytes are also used as targets for gene transfer but the 
efficiency of transfection is in general low. We therefore investigated whether our targeting 
vectors transduce primary murine keratinocytes (MK). All three targeting vectors indeed 
transduced MK albeit with significant differences in efficiency (Fig. S3A). The highest 
transduction efficiency (30.9% +/- 1.4%) was determined for AAV-Kera2, followed by AAV-
Kera3 (20.2 +/- 2.5%) and AAV-Kera1 (15.9 +/- 2.3%). Of note, in contrast to HK, which are 
refractory to AAV2 transduction, incubation of MK with AAV2 lead to a transduction 
efficiency of 12.3% +/- 0.8%. Thus, while AAV-Kera1 and AAV-Kera3 showed a similar 
efficiency than AAV2, AAV-Kera2 was significantly more efficient in transducing MK. 
Next, we tested whether AAV-Kera2 is capable of transducing differentiated murine 
keratinocytes. We therefore applied AAV-Kera2 or PBS on the top layer of 15-day-old 
murine 3D organotypic skin cultures and determined transgene expression 72 hrs later (Fig. 
S3B). While no positive cells could be detected in PBS-treated cultures, GFP signals were 
observed in the upper keratinocyte layer suggesting that also differentiated murine 
keratinocytes are targets for AAV-Kera2 transduction. 
 
Identification of candidate receptor by comparative gene analysis 
So far, receptors used by AAV targeting vectors selected in high-throughput screens remained 
elusive, a drawback that may hamper their clinical use due to safety issues. Prompted by the 
success of comparative gene analysis (CGA), a microarray-based bioinformatic approach, in 
identifying receptors involved in transduction of natural occurring viruses26-29, we here aimed 
to exploit this method to map the receptor engaged by AAV-Kera2, the most efficacious of 
our three novel targeting vectors.  
We therefore incubated 51 cell lines of the NCI60 cell line panel with AAV-Kera2 and – for 
comparison – with AAV2 followed by correlation of viral transduction with the cellular 
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expression profile of all genes in the COMPARE database. Genes associated with AAV-
Kera2 transductions with a score equal or greater than 0.6 are shown as example in Table S2.  
The highest score for a cell membrane protein for AAV-Kera2 was obtained for ITGB8 (a 
pearson correlation coefficient of 0.72), the β8 integrin subunit. This gene positively 
correlated with multiple entries in the database (Table 2). In contrast, ITGB8 appeared only 
once in the list of genes that correlated with AAV2 transductions (pearson correlation 
coefficient value of 0.41).  
 
αvβ8 integrin serves as receptor for AAV-Kera2 
The β8 integrin subunit solely forms heterodimers with the αv integrin subunit.30 This 
integrin is expressed on HK (Fig. 6A), but not on NIH3T3, BLM or HepG2 cells (Fig. 6B), 
the cell lines for which AAV-Kera2 did not show tropism (Fig. 3). As control for this, and as 
a defined model cell line for subsequent experiments, we included SW480αvβ8 (Fig. 6B). 
This cell line stably expresses αvβ8 integrin as well as other αv-containing integrins, while 
SW480, the parental cell line, expresses αv-, but not αvβ8 (Fig. S4A).31-32 Both cell lines 
were transduced with equal efficacy by AAV2 (Fig. S4B). In contrast, we measured a 
significant higher transduction efficiency of AAV-Kera2 on SW480αvβ8 compared to 
SW480 cells (Fig. S4B), which is in concordance with involvement of αvβ8 integrin in AAV-
Kera2-mediated transductions.  
αvβ8 integrin belongs to the group of integrins internalized through the clathrin pathway.33 
Thus, blocking this pathway by chlorpromazine that inhibits assembly of clathrin lattices34, 
should affect AAV-Kera2-mediated transduction of HK. As control, we performed cell 
transductions in the presence of genistein, which inhibits caveolin-mediated uptake.35 In the 
presence of genistein the transduction rate of AAV-Kera2 was improved (Fig. 6C), maybe as 
result of an enhanced cellular uptake activity induced by inhibition of the caveolin pathway. 
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In contrast and – in line with our hypothesis -, addition of chlorpromazine and - thus 
inhibition of the clathrin pathway - significantly reduced the transduction efficiency of this 
vector (Fig. 6D).  
To provide further evidence for the involvement of αvβ8 integrin, we determined 
transduction efficiencies in the presence and absence of αv- or αvβ8-blocking antibodies. 
Neither the addition of αv- nor of αvβ8-blocking antibodies negatively affected cell 
transductions by AAV2. Conversely, transductions by AAV-Kera2 were remarkably inhibited 
by 64.3 % (anti-αv, Fig. 6E) or 44.3% (anti-αvβ8, Fig. 6F), respectively. 
In support of these experimental data, sequence alignments revealed a striking homology 
between the AAV-Kera2 peptide sequence (PRGDLAP) and the binding motif (RGDLATI) 
of the high-affinity αvβ8 integrin ligand latency associated peptide (LAP) of the 
Transforming Growth Factor-β (TGF-β).31-32  
 
Discussion  
Human skin equivalents are applied in conditions of impaired healing such as chronic wounds 
or large skin burns. While the pro-inflammatory micromilieu represents an important barrier 
for initial engraftment36, inadequate perfusion hampers long-term persistence of the skin 
equivalent.37 Genetic modification of keratinocytes represents an attractive strategy to resolve 
these problems. Furthermore, cutaneous gene therapy may also be applied to a wide range of 
inherited skin blistering or barrier diseases for which no causal treatment is available yet.38 To 
push cutaneous gene therapy towards clinical application, efficient and safe delivery tools are 
required. Here, we developed three highly efficient AAV targeting vectors (AAV-Kera1, 
AAV-Kera2 and AAV-Kera3) for genetic manipulation of human primary keratinocytes 
(HK), which transduce not only HK seeded as monolayers (Fig. 2), but also showed tropism 
for keratinocytes in the presence of feeder cells (Fig. 4). An important prerequisite for 
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potential clinical use of vectors across the skin barrier is the ability to transduce differentiated 
keratinocytes. Applying our novel vectors to airlifted differentiated organotypic skin cultures 
revealed that in particular AAV-Kera2 is capable of transducing differentiated keratinocytes 
in 3D skin cultures (Fig. 5 and Fig. S3B). Our study is also the first that succeeded to identify 
a distinct receptor targeted by a capsid-modified vector selected in a directed evolution 
approach. Specifically, comparative gene analysis (CGA) revealed αvβ8 integrin as receptor 
engaged by AAV-Kera2, establishing thereby CGA as strategy to map receptors of capsid-
modified vectors, and identified αvβ8 integrin as a promising novel candidate receptor for 
cutaneous gene therapy, which is of particular importance given the limited knowledge on 
receptors that can be exploited for modification of HK. These technical improvements open 
up the avenue for a plethora of new applications. More specifically, the novel vectors for 
example represent a promising tool for application in basic research and pre-clinical models, 
where they are expected to promote the analysis of protein function in keratinocyte 
monocultures and more importantly in skin equivalents by improving the efficiency of gene 
silencing, gene addition or gene correction approaches. This may lead to the development of 
novel treatment strategies including cutaneous gene therapy approaches. In this respect, 
AAV-Kera2’s ability to transduce both primary human and murine keratinocytes (Fig. 2 and 
Fig. S3) is an important advantage. Moreover, in a clinical setting, the novel targeting vectors 
and here again in particular AAV-Kera2 represent efficient delivery tools for anti-
inflammatory or pro-angiogenic genes to HK in order to improve engraftment and survival of 
skin transplants.36,37 Since AAV-Kera2 possess the ability to transduce also differentiated 
keratinocytes, the here-developed vectors are expected to also improve gene transfer 
efficiency following direct injection onto the wound bed. Finally, due to the knowledge on 
AAV-Kera2’s receptor, local application of the vector to αvβ8 integrin-positive skin layers 
might possibly be used for in vivo gene transfer even in non-wounded skin. 
Our novel vectors are based on AAV2, which do not show a natural tropism for keratinocytes 
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(Fig. 1A). Mechanistically, both cell entry and post entry barriers may hamper gene transfer 
efficiency. An example for the latter was previously reported by Braun-Falco and colleagues 
who improved keratinocyte transductions by addition of MG132, a proteasome inhibitor, or of 
AG1478, an epidermal growth factor receptor protein tyrosine kinase (EGFR-PTK) inhibitor8. 
Both drugs impair degradation of incoming AAV2 particles by directly blocking proteasomal 
degradation (MG132) or by impairing EGFR-PTK-mediated phosphorylation of tyrosine 
residues of the AAV capsid, which promotes ubiquitination and thus degradation.39-40  
Our study is indicative of the presence of an additional barrier, namely, the lack of HSPG 
(Fig. 1B). This cell surface molecule is a component of the extracellular matrix and serves as 
attachment receptor for AAV2.24 Site-directed mutagenesis of the HSPG binding motif16-17 or 
presence of heparin, a soluble analogue of HSPG, during vector application renders AAV2 
non-infectious24 revealing the importance of HSPG for cell transduction. In order to explain 
this dependency, Asokan and colleagues postulated a conformational change of the capsid - 
induced by its binding to HSPG - that is required for binding to the internalization receptors.22 
So far, two different receptors for cell entry have been reported, α5β1 and αvβ5 integrin22-23, 
which – in contrast to HSPG - are both present on HK (Fig. 1B).  
The AAV peptide display technology represents a powerful tool to screen for viral variants 
that overcome both, pre- and post-entry barriers, since this evolutionary approach selects for 
mutants capable of fulfilling the whole viral lifecycle, i.e. generate progeny following target 
cell infection.19-21, 41-44 For selection of AAV variants targeting HK, we used our previous-
described library of mutants displaying 7-mer random peptides at amino acid position 587.20 
Using this position for peptide insertion results in natural receptor-blinded mutants as the two 
main residues of the HSPG binding motif, R585 and R588, become separated.16-18 Compared 
to previous AAV peptide display screens, we here implemented three technical 
improvements, which we believe are critical for selection of efficient targeting vectors with a 
re-directed tropism: i) the use of different donors in each selection round to avoid bias for 
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receptors expressed in a donor-specific manner, ii) continuous increase of the selection 
pressure by lowering the vg/cell ratio aiming to select for the fittest variants and iii) the use of 
a library that had been depleted for AAV variants displaying HSPG binding peptides. 
Although HK lack HSPG expression, the latter step was included since mutants displaying 
such peptides like AAV2 tend to show a broad tropism45 and to accumulate in liver and 
spleen18, which should be avoided in cutaneous gene therapy. 
Sequencing of the viral progeny revealed selection of nine different peptide motifs (Table 1), 
three of which were chosen for further analyses based on the frequency of their occurrence 
(Kera1 and Kera3) or on the unique combination of prominent features (Kera2). All three 
targeting vectors (AAV-Kera1, -Kera2 and -Kera3) not only showed a donor-independent 
impressive increase in entry and transduction efficiency compared with AAV2 (Fig. 2 and 
Fig. S2), but also – in line with our hypothesis - a remarkable re-direction of the tropism 
towards HK (Figs. 2-4) arguing for the efficacy of our selection strategy. 
Comparison with serotypes others than AAV2 further highlights the potency of the here-
developed vectors. Ellis and colleagues compared nine different natural AAV serotypes 
(AAV1-AAV9) on 34 different cell lines and primary cell types amongst them HK and 
primary murine keratinocytes (MK)9. The vectors - like ours - encoded for GFP controlled by 
the CMV promoter in a self-complementary vector genome conformation. In contrast to our 
study, however, they performed all experiments with a vg/cell ratio of 10e5. Of the nine 
serotypes, AAV6 was the most efficient vector transducing 80% of HK, followed by AAV1 
(74%) and AAV3 (15%). Importantly, using a 20-fold lower vg/cell ratio, i.e. 5x10e3 vg/cell, 
we reached transduction efficiencies comparable to the most efficient serotype (AAV6), 
namely up to 83.8% (Fig. 4). The same was true for MK, for which AAV1 is reported to be 
the most efficient serotype 9. Again, using a 20-fold lower vg/cell ratio an equal transduction 
efficiency of was reached (AAV1: 29% with a vg/cell ratio of 10e59 vs. AAV-Kera2: 30.9% 
+/- 1.4% with a vg/cell ratio of 5x10e3 (Fig. S3A)). Thus, with the here-developed vectors 
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significantly lower particle numbers have to be applied to obtain transduction efficiencies 
similar to AAV1 and AAV6, the so far most efficient serotypes for primary keratinocytes.  
Since each target cell type expresses a plethora of cell surface molecules, potentially serving 
as receptor, it is technically impossible to use high-throughput screens like the AAV peptide 
display for the selection of mutants specifically targeting a certain, beforehand chosen 
receptor. Due to the limited size of the selected peptide, it is also extremely unlikely to 
decipher the targeted receptor by a common data bank search. Thus, characterization of a 
specific receptor involved in re-targeting represents an important so far unresolved challenge. 
To this end, we here exploited CGA as a novel strategy to identify the receptor targeted by the 
PRGDLAP peptide of AAV-Kera2, the targeting vector with the most striking tropism for 
HK. This screen revealed ITGB8, the integrin subunit β8, as candidate. β8 is unique as it is 
solely described as heterodimer with αv.30 The only high-affinity ligand of αvβ8 integrin is 
the latency-associated peptide (LAP) of TGF-β32, which becomes thereby sequestered, a 
process crucial for maintaining epithelial homeostasis.32, 46 The binding of LAP to αvβ8 
integrin is mediated by a RGDLATI motif located in the C’-terminal part of LAP, specifically 
at amino acid positions 244-250. Our selected peptide is a truncated version of this ligand as it 
contains the RGDLA motif flanked by two proline residues, which may stabilize this motif 
when displayed at the tip of the capsid peaks. Experimental evidence that αvβ8 serves as 
receptor for AAV-Kera2 is provided by the presence of this integrin on the target cells (Fig. 
6), the tropism of AAV-Kera2 for cells expressing αvβ8 integrin (compare Fig. 6 A,B with 
Figs. 2 and 3; Fig. S4) and the significant inhibition of cell transduction in the presence of 
αv- or αvβ8-blocking antibodies (Fig. 6 E,F).  
In summary, we here report on the development of three AAV2-based vectors for 
keratinocyte-directed gene transfer approaches that overcome the refractoriness of 
keratinocytes by targeting novel receptors. All three vectors showed tropism for keratinocytes 
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in mono- and mixed cultures and for differentiated keratinocytes in organotypic 3D cultures, 
while transduction of off-target cell types remained at background level. Furthermore, we 
report on the first successful approach to identify candidate receptors engaged by tropism-
modified AAV vectors, which as consequence revealed αvβ8 integrin as a promising 
candidate receptor for cutaneous gene therapy.  
 
Material and Methods 
Cell lines and primary cells 
The human embryonic kidney cell line HEK293 (ATCC number: CRL-1573), the human 
cervix carcinoma cell line HeLa (ATCC number: CCL-2), the human hepatoma cell line 
HepG2 (ATCC number: HB-8065), the human adenocarcinoma cell line SW480 and its 
derivative SW480αvβ8 31 as well as the murine fibroblast cell line NIH3T3 (ATCC number: 
CRL-1658TM) were maintained in Dulbecco’s modified Eagle’s medium (DMDM) with 
GlutaMAX-I (Invitrogen, Karlsruhe, Germany). The human melanoma cell line BLM (kindly 
provided by Cornelia Mauch, University of Cologne, Germany) and the NCI60 cell line panel 
were maintained in RPMI-1640 medium with GlutaMAX-I (Invitrogen). All media were 
supplemented with 10% fetal calf serum (Invitrogen), 100 IU/ml of penicillin (Invitrogen) and 
100 µg/ml of streptomycin (Invitrogen). The medium of SW480αvβ8 and of the NCI60 cell 
line panel additionally contained 4 µg/ml of puromycin (Invitrogen) and L-Glutamine 2 mM 
(Invitrogen), respectively. 
HK were isolated from human foreskin of healthy donors after informed consent (ethics 
committee vote: 12-163). Foreskin was separated manually into dermis and connective tissue. 
Dermis was minced into small pieces, transferred into Dispase II solution (10 mg/ml in 
DMEM/GlutaMAXTM-I (Invitrogen)) and incubated for 24 hrs at 4°C. Epidermis was 
detached from the dermis, followed by cell separation through trypsin/EDTA treatment. The 
suspension was filtered, pelleted by low speed centrifugation and cell pellet was re-suspended 
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in CnT Basal Medium 1 (CELLnTEC Advanced Cell Systems AG, Bern, Switzerland). 
Primary keratinocytes were isolated and cultured in minimal Ca2+ medium (50 µM Ca2+) as 
described.47  
 
Antibodies and evaluation of cell surface expression of integrins and HSPG 
For determining cell surface expression of integrins and HSPG, respectively, the following 
antibodies were used: mouse anti-human αvβ5 antibody (MAB1961, Millipore, Schwalbach, 
Germany), mouse anti-human α5β1 antibody (MAB1999, Millipore), mouse anti-human αv 
antibody (MAB1953, Millipore), mouse anti-human αvβ8 antibody (37E5,31) and mouse anti-
human heparan sulfate delta (USBiological, Massachusetts, USA). Cells were harvested by 
mechanically scraping, pelleted and re-suspended in 1xPBS. Indicated primary antibody was 
added and cells were incubated 15 min. on ice followed by a washing step. Secondary 
antibody (goat anti mouse IgG, Southern Biotech, Eching, Germany) was added to cell 
suspension in 1xPBS. Following incubation on ice for 15 min. and a further washing step, 
cells were analyzed by flow cytometry. A minimum of 10,000 cells was counted for each 
sample. Unstained cells and cells that were only treated with secondary antibody were used as 
controls. 
 
Selection of AAV capsid mutants on primary human keratinocytes 
AAV peptide display selection on HK was performed using a library of AAV capsid insertion mutants 
depleted for mutants capable of binding to HSPG by heparin affinity chromatography.18 Selection 
pressure was increased from round 1 to 5 by reducing the vg/cell number from 1000 to 1. Following 
the 5th selection round, viral progeny was isolated and sequenced (Qiagen, Hilden, Germany).20 The 
AAV helper plasmids pRC-Kera1, pRC-Kera2 and pRC-Kera3 were obtained by subcloning the 
BsiwI/SnaBI fragment of the AAV genome containing the respective insert sequences (Table 1) into 
pRC-K17 from which the corresponding region had been removed.  
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Production of recombinant AAV vectors 
HEK293 cells were seeded at 80% confluency and co-transfected with a total of 37.5 µg of 
pRC48, pscAAV/EGFP49 and pXX650 for AAV2 production. For production of targeting 
vectors, pRC was exchanged for pRC-Kera1, pRC-Kera2 and pRC-Kera3, respectively. 
Forty-eight hours post-transfection, cells were harvested, lysed and purified by iodixanol 
density step gradient centrifugation.49 Genomic particle titers were determined by qPCR 
(LightCycler System, Roche Diagnostics, Mannheim, Germany) using transgene specific 
primers.45 The capsid titer was determined by enzyme-linked immunosorbent assay using the 
AAV2 capsid-specific antibody A20 (Progen, Heidelberg, Germany). 
 
Quantification of entry and transduction efficiency 
For determining entry efficiency HK, seeded at 70-80% confluency in collagen pre-coated 
wells, were incubated with the indicated vg/cell ratio for 30 min. on ice and then shifted to 
37°C and 5 % CO2. Cells were harvested one h p.t. The cells were washed and membrane-
bound vector particles were removed by trypsin treatment.45 Cell pellet was washed twice 
with 1xPBS and total viral DNA was isolated (DNeasy Tissue Kit, Qiagen). Relative 
quantification of vector genomes (GFP) and reference gene (PLAT) was performed by qPCR 
(Roche Diagnostics).45 The specificity of target and reference gene amplification was 
confirmed by melting-curve analysis. GFP values were normalized to PLAT levels using the 
LightCycler 480 software 1.5 (Roche Diagnostics). 
For determining transduction efficiency, HK or indicated cell lines were incubated with the 
indicated vg/cell ratio for 48 hrs, while MK were incubated with 5x10e3 vg/cell for 72 hrs, 
followed by flow cytometry measurements (BD FACS Calibur). A minimum of 10,000 cells 
was counted for each sample. Background fluorescence was set to 1%. For mixed cultures, 
HK and NIH3T3 fibroblasts were seeded at a ratio of 1:1. Briefly, NIH3T3 cells were seeded 
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in a collagen pre-coated 24-well-plate and cultivated for five hrs. Medium was carefully 
aspirated and HK were added. The number of HK were determined 24 hrs later and mixed 
cultures were incubated with 5x10e3 vg/HK for 48 hrs at 37°C. Cells were harvested, stained 
with anti-Feeder antibody (monoclonal, APC conjugated mouse anti-human, Miltenyi, 
Bergisch Gladbach, Germany) and GFP-positive as well as APC-positive cells were 
determined by flow cytometry as described above. 
 
Competition and inhibition experiments 
HK, seeded in collagen pre-coated wells, were incubated with chlorpromazine at a final 
concentration of 16 µg/ml or with genistein at a final concentration of 648 µM for 30 min. at 
37°C or left untreated. Vectors were added at the indicated vg/cell ratio to drug-treated or -
untreated cells. Drug treatment was stopped at indicated time points p.t. by washing, followed 
by extensive treatment with trypsin and re-seeding of cells in fresh medium again on pre-
coated plates. For peptide competition experiments, HK were incubated with 300 µM 
GRGDS or GRGES peptides or left untreated for 15 min. at 37°C. Subsequently, vectors were 
added at the indicated vg/cell ratio. At four hrs p.t. cells were harvested and re-seeded as 
described before. For the antibody blocking experiments cells were either incubated with 2 
µg/ml αv-blocking antibody (Millipore) for 15 min. at 37°C or with 200 µg/ml of αvβ8-
blocking antibody31 for 30 min. on ice, followed by vector incubation. Cells incubated with 
vectors in the absence of antibodies served as control. Vectors were removed after four hrs 
(αv) or 30 min. (αvβ8). Transduction efficacy was determined 48 hrs p.t. by flow cytometry. 
 
Correlation of AAV-Kera2 transduction with NCI60 cell panel microarray gene 
expression pattern 
Fifty-one cell lines of the NCI60 panel were transduced with serially diluted AAV2 or AAV-
Kera2 vectors. 48 hrs p.t. cells were harvested and analyzed by flow cytometry to quantify 
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GFP-positive cells using a BD FACSArray. The relative transduction efficiencies of the fifty-
one cell lines were expressed as a pattern which we then used as a seed file for comparison to 
the patterns in the Developmental Therapeutics Program (DTP), National Cancer Institute 
(NCI) database, using the COMPARE algorithm (http://dtp.nci.nih.gov/compare-web-
public_compare/login.do). This algorithm determines the similarity of patterns between the 
given 'seed' and others within a database by creating a scalar index of similarity expressed 
quantitatively as a pearson correlation coefficient. The output of the COMPARE program is a 
rank-ordered list (by pearson correlation coefficient) of the most highly correlated patterns 
from the database. 
 
Transduction of organotypic human 3D skin cultures 
A dermal equivalent consisting of a collagen gel populated with NIH3T3 fibroblasts was 
cultivated in DMEM/GlutaMAXTM-I medium supplemented with 10 % FCS (Invitrogen), 
100 U/ml penicillin (Invitrogen), 100 µg/ml streptomycin (Invitrogen), 10 µg/ml 
Transforming Growth Factor-α (Sigma-Aldrich, Taufkirchen, Germany), 10 µg/ml EGF 
(Sigma-Aldrich) and 50 µg/ml sodium L-ascorbate (Sigma-Aldrich). In case of the 
organotypic murine 3D skin culture, the collagen gel populated with NIH3T3 fibroblasts was 
cultivated in DMEM/Ham’s F12 medium (Sigma-Aldrich) supplemented with 10 % FCS 
Gold (PAA, Coelbe, Germany), 100 U/ml penicillin (Invitrogen), 100 µg/ml streptomycin 
(Invitrogen), 2 mM L-Glutamine (Life Technologies GmbH, Darmstadt, Germany), 10 µg/ml 
EGF (Sigma-Aldrich), 50 µg/ml sodium L-ascorbate (Sigma-Aldrich), 5 µg/ml Insulin 
(Sigma-Aldrich), 0.5 µg/ml Hydrocortisone (Sigma-Aldrich), 1x10e-10M cholera toxin 
(Sigma-Aldrich) and 0.2 mM CaCl2. Keratinocytes were seeded in glass rings on top of the 
collagen gel submerged in medium for 24 hrs at 37°C. Glass rings were removed, medium 
was changed every other day with the liquid level just sufficient to contact the collagen gel, 
leaving the keratinocyte layer exposed to air. To transduce human or murine keratinocytes, a 
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sterile glass ring was put on top of the keratinocyte layer and filled with medium containing 
the indicated vector solution or 1xPBS. Two hrs p.t., vector containing solution or 1xPBS was 
carefully removed. Organotypic cultures were cultivated for further 72 hrs at 37°C and 
subsequently fixed in 2% PFA in 3.5% Sucrose/1xPBS for 30 min. at room temperature and 
embedded in Tissue Tek (Sakura Finetek, Zoeterwoude, Netherland). Cryo-sections (5 µm) 
were mounted by IS Mounting Medium DAPI (Dianova, Hamburg, Germany) and analyzed 
microscopically.  
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Table S1. Packaging efficiency of AAV targeting vectors 
Table S2. Genes associated with AAV-Kera2 transduction  
Fig. S1. Schematic overview of AAV peptide display selection 
Fig. S2. Transduction efficiency of targeting vectors on primary human keratinocytes 
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Fig. S3. Transduction efficiency of targeting vectors on primary murine keratinocytes 
Fig. S4. Presence of αvβ8 integrins improves cell transduction 
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Table 1. Sequence and frequency of peptide insertions selected by AAV peptide display.  
isolate 
sequence 
of insert 
frequency net charge 
Kera1 RGDTATL 17 neutral 
Kera2 PRGDLAP 2 neutral 
Kera3 RGDQQSL 4 neutral 
Kera4 RSDLASL 3 neutral 
Kera5 PRGELAP 1 neutral 
Kera6 GRGDLAP 2 neutral 
Kera7 RGDTASL 1 neutral 
Kera8 PRGDLRP 4 positive 
Kera9 RGDQHSL 1 positive 
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Table 2. The output of the COMPARE analysis. Shown are the first six cell membrane 
genes that were associated with AAV-Kera2 transduction profile of the NCI60 cell panel. 
GeneCards symbols, number of hits and the range of scores as pearson correlation coefficient 
are also listed. 
Gene Symbol Hits Pearson Correlation Coefficient 
Integrin, beta 8 ITGB8 11 0.72 to 0.5 
Glypican 4 GPC4 3 0.67 to 0.65 
Enabled homolog (Drosophila) ENAH 3 0.63 to 0.53 
Transmembrane and coiled-coil domain 
family 1 TMCC1 4 0.6 to 0.51 
Prostaglandin-endoperoxide synthase 1 PTGS1 3 0.59 to 0.51 
kinesin family member 3A KIF3A 2 0.56 to 0.52 
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Figure legends 
Fig. 1. Lack of receptor expression renders primary human keratinocytes refractory to 
transduction by AAV2  
(A) Primary human keratinocytes (HK) isolated from foreskins of three different healthy 
donors were incubated with 5x10e3 vector genome containing particles (vg) per cell of 
AAV2. The AAV2 vector encoded for enhanced green fluorescent protein (GFP) in a self-
complementary vector genome conformation. Percentage of transgene expressing cells was 
quantified by flow cytometry 48 hrs post transduction (p.t.). Mean of three independent 
experiments +/- SD is shown. (B) HK and - as control - the cervix carcinoma cell line HeLa 
were stained with mouse anti-human αvβ5, mouse anti-human α5β1 or mouse anti-human 
HSPG antibody, followed by a PE-labeled IgG secondary antibody. The percentage of cells 
positive for HSPG or integrin expression was quantified by flow cytometry. Mean of three 
independent experiments +/- SD is shown.  
 
Fig. 2. AAV targeting vectors show a peptide-mediated superior cell entry and 
transduction efficiency on human primary keratinocytes 
HK seeded on collagen-pre-coated plates were incubated with the three AAV targeting 
vectors, AAV-Kera1 (“Kera1”), AAV-Kera2 (“Kera2”) and AAV-Kera3 (“Kera3”), and 
AAV2, respectively. (A) For measuring cell entry efficiency, cells were incubated with 
5x10e2 vg/cell. Cell transductions were stopped by extensive trypsin treatment to remove 
membrane-bound particles. Intracellular vector particles were quantified by qPCR and 
normalized to the housekeeping gene Plasminogen activator (PLAT). Values obtained for 
AAV2 were set to 1. n=3, **=p<0.01, ***=p<0.001. (B) HK seeded on collagen-pre-coated 
slides were incubated with indicated vectors (5x10e4 vg/cell) for 24 hrs and analyzed 
microscopically. Magnification: 40x. (C) HK were incubated with 5x10e3 vg/cell of AAV2 or 
with 7.5x10e2 vg/cell of the targeting vectors in the presence or absence of 300 µM GRGDS 
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or GRGES peptides. The percentage of transgene (GFP) expressing cells was quantified by 
flow cytometry 48 hrs p.t. Mean of three independent experiments +/- SD is shown. 
*=p<0.05, **=p<0.01. 
 
Fig. 3. AAV targeting vectors show target cell selectivity  
The human melanoma cell line BLM (A), the human hepatoma cell line HepG2 (B) and the 
mouse fibroblast cell line NIH3T3 (C) were incubated with increasing vg/cell ratios (10-
5x10e3) of AAV-Kera1 (“Kera1”), AAV-Kera2 (“Kera2”) and AAV-Kera3 (“Kera3”), or 
AAV2, respectively. The percentage of transgene (GFP) expressing cells was quantified by 
flow cytometry 48 hrs p.t. Mean of three independent experiments +/- SD is shown.  
 
Fig. 4. Selective transduction of human primary keratinocytes in mixed cultures 
HK were co-cultured with NIH3T3 cells and incubated with the three targeting vectors for 48 
hrs. Cells were harvested and stained with an anti-Feeder antibody. Whole cell population 
stained with anti-Feeder antibody is indicated in the left column. Percentage of transduced 
cells in “A” and “B” was then determined. Percentage of GFP-expressing, but anti-Feeder 
negative cells (population “A”, representing HK) is indicated in the middle, while percentage 
of GFP-expressing, anti-Feeder positive cells (population “B”, representing fibroblasts) is 
shown in the right column. One representative experiment of three is shown. 
 
Fig. 5. AAV targeting vectors transduce differentiated keratinocytes in organotypic 
cultures 
Keratinocytes in organotypic 3D skin cultures grow airlifted on the top of a collagen matrix 
containing fibroblasts. 16-day-old human 3D skin cultures were incubated with AAV2 (A) or 
AAV targeting vectors (B) by dropping the vector solution into a glass ring placed on the top 
layer. Control cultures received 1xPBS (A). Vector solution was carefully and exhaustively 
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removed after two hrs, followed by culturing of the skin equivalents for further 72 hrs. 
Samples were fixed and cryo-sections were mounted in IS Mounting Medium DAPI. 
Magnification for (A): 20x; magnification for (B) 40x. 
 
Fig. 6. αvβ8 integrin serves as receptor for AAV-Kera2 
(A) HK seeded on collagen pre-coated plates as well as (B) SW480αvβ8, BLM, HepG2 and 
NIH3T3 cells were stained with anti-human αvβ8 antibody, followed by incubation with PE-
conjugated secondary antibody and flow cytometric measurements. (C) HK were incubated 
with 5x10e3 vg/cell of AAV-Kera2 (“Kera2”) or AAV2 in the absence (black) and presence 
(grey) of genistein (175 µg/ml). (D) HK were incubated with 3x10e3 vg/cell of AAV-Kera2 
or 5x10e3 vg/cell of AAV2 in the absence (black) and presence (grey) of chlorpromazine (16 
µg/ml). (E) SW480αvβ8 cells were incubated w/o (black) or with (grey) 2 µg/ml of the αV-
blocking antibody, followed by addition of 6x10e2 vg/cell of AAV2 and AAV-Kera2, 
respectively. (F) SW480αvβ8 cells were incubated w/o (black) or with (grey) 200 µg/ml 
αvβ8-blocking antibody, followed by addition of 7.5x10e2 vg/cell of AAV2 and 3x10e3 
vg/cell of AAV-Kera2, respectively. The percentage of GFP-expressing cells (D-F) was 
quantified by flow cytometry 48 hrs p.t. In (A) one representative experiment of three is 
shown. Values of (B) – (F) represent the mean of three independent experiments +/- SD. In 
(E) and (F) values for non-antibody treated cells were set to 1. ns = non significant, *=p<0.05, 
**=p<0.01, ***=p<0.001 
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